Lu 29-252
Appearance
Clinical data | |
---|---|
Other names | Lu-29-252; LU-29252; LU29252; Lu 29–252 |
Drug class | Sigma σ2 receptor ligand |
Identifiers | |
| |
PubChem CID | |
PubChem SID | |
Chemical and physical data | |
Formula | C28H36N2O2 |
Molar mass | 432.608 g·mol−1 |
3D model (JSmol) | |
| |
|
Lu 29-252 is a selective sigma σ2 receptor ligand which was under development for the treatment of anxiety disorders but was never marketed.[1][2][3][4][5] It reached the preclinical stage of development prior to the discontinuation of its development.[1] The drug was under development by Lundbeck.[1]
References
[edit]- ^ a b c "LU 29252". AdisInsight. Springer Nature Switzerland AG. 23 May 1995. Retrieved 22 October 2024.
- ^ "LU-29252". Therapeutic Target Database (TTD). D0T8HU. Retrieved 22 October 2024.
- ^ Gronier B, Debonnel G (March 1999). "Involvement of sigma receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems". European Journal of Pharmacology. 368 (2–3): 183–196. doi:10.1016/s0014-2999(99)00025-4. PMID 10193654.
- ^ Abaimov DA, Kovalev GI (2011). "Sigma receptors as a pharmacological target for neuroprotectors. New horizons of pharmacotherapy of Parkinson disease". Neurochemical Journal. 5 (2). Pleiades Publishing Ltd: 83–91. doi:10.1134/s1819712411010028. ISSN 1819-7124.
- ^ Rousseaux CG, Greene SF (August 2016). "Sigma receptors [σRs]: biology in normal and diseased states". Journal of Receptor and Signal Transduction Research. 36 (4): 327–388. doi:10.3109/10799893.2015.1015737. PMC 4906365. PMID 26056947.